• 9280 Citations
  • 38 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Outputs

2020

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.

Research output: Contribution to journalArticle

Open Access
File
1 Citation (Scopus)
1 Downloads (Pure)

Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma

Bhatnagar, A., McKay, M. J., Arasaratnam, M., Crumbaker, M., Gurney, H. & Molloy, M. P., 31 May 2020, In : Journal of Mass Spectrometry. 55, 10, 8 p., e4584.

Research output: Contribution to journalArticle

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics

Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J. & Shaw, P. J., 21 Feb 2020, In : Bone Marrow Transplantation. 3 p.

Research output: Contribution to journalLetter

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Procopio, G., McDermott, D. F., Castellano, D., Choueiri, T. K., Donskov, F., Gurney, H., Oudard, S., Richardet, M., Peltola, K., Alva, A. S., Carducci, M., Wagstaff, J. & 11 others, Chevreau, C., Fukasawa, S., Tomita, Y., Gauler, T. C., Kollmannsberger, C. K., Schutz, F. A., Larkin, J., Cella, D., McHenry, M. B., Saggi, S. S. & Tannir, N. M., 16 Jul 2020, In : Cancer. 12 p.

Research output: Contribution to journalArticle

Nuances to precision dosing strategies of targeted cancer medicines

Hopkins, A. M., Menz, B. D., Wiese, M. D., Kichenadasse, G., Gurney, H., McKinnon, R. A., Rowland, A. & Sorich, M. J., 1 Aug 2020, In : Pharmacology Research & Perspectives. 8, 4, 9 p., e00625.

Research output: Contribution to journalReview article

Open Access
File

Patient-reported outcomes from the phase III Randomized IMmotion151 trial: atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma

Atkins, M. B., Rini, B. I., Motzer, R. J., Powles, T., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Gurney, H., Oudard, S., Uemura, M., Lam, E. T., Grullich, C., Quach, C., Carroll, S., Ding, B., Zhu, Q. C., Piault-Louis, E., Schiff, C. & 1 others, Escudier, B., 1 Jun 2020, In : Clinical Cancer Research. 26, 11, p. 2506-2514 9 p.

Research output: Contribution to journalArticle

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., Tykodi, S. S. & 9 others, Grimm, M. O., Gurney, H., Leibowitz-Amit, R., Geertsen, P. F., Amin, A., Tomita, Y., McHenry, M. B., Saggi, S. S. & Tannir, N. M., 12 Jul 2020, In : Journal for ImmunoTherapy of Cancer. 8, 2, p. 1-12 12 p., e000891.

Research output: Contribution to journalArticle

Open Access
File

The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training

Lam, T., Birzniece, V., McLean, M., Gurney, H., Hayden, A. & Cheema, B. S., 13 Feb 2020, In : Sports Medicine - Open. 6, 1, p. 1-14 14 p., 13.

Research output: Contribution to journalReview article

Open Access
File
1 Citation (Scopus)

The AGITG GAP Study: a Phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer

Barbour, A. P., Samra, J. S., Haghighi, K. S., Donoghoe, M. W., Burge, M., Harris, M. T., Chua, Y. J., Mitchell, J., O’Rourke, N., Chan, H., Gebski, V. J., Gananadha, S., Croagh, D. G., Kench, J. G., Goldstein, D. & Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators, 1 Jul 2020, In : Annals of Surgical Oncology. 27, 7, p. 2506-2515 10 p.

Research output: Contribution to journalArticle

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M. O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P. & 5 others, Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A. & Albiges, L., Aug 2020, In : Annals of Oncology. 31, 8, p. 1030-1039 10 p.

Research output: Contribution to journalArticle

Open Access
File
1 Citation (Scopus)
2019

A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy

Lam, T., McLean, M., Hayden, A., Poljak, A., Cheema, B., Gurney, H., Stone, G., Bahl, N., Reddy, N., Shahidipour, H. & Birzniece, V., 1 May 2019, In : Endocrine Connections. 8, 5, p. 605-615 11 p.

Research output: Contribution to journalArticle

Open Access
File
7 Downloads (Pure)

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 others, Bedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

Research output: Contribution to journalArticle

136 Citations (Scopus)

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 others, Mariani, M., Robbins, P. B., Chudnovsky, A., Fowst, C., Hariharan, S., Huang, B., Di Pietro, A. & Choueiri, T. K., 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.

Research output: Contribution to journalArticle

350 Citations (Scopus)
1 Citation (Scopus)

Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

Al-Mansouri, L. & Gurney, H., 1 Dec 2019, In : Asia-Pacific Journal of Clinical Oncology. 15, 6, p. 288-295 8 p.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Al-Mansouri, L., Arasaratnam, M. & Gurney, H., 14 Jun 2019, In : European Journal of Hospital Pharmacy.

Research output: Contribution to journalArticle

Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

Arasaratnam, M., Crumbaker, M., Bhatnagar, A., McKay, M. J., Molloy, M. P. & Gurney, H., Jul 2019, In : Cancer Chemotherapy and Pharmacology. 84, 1, p. 139-146 8 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthélémy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B. & 19 others, Melichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M. O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grünwald, V., McHenry, M. B., Mekan, S., Tannir, N. M. & CheckMate 214 Investigators, 1 Oct 2019, In : The Lancet Oncology. 20, 10, p. 1370-1385 16 p.

Research output: Contribution to journalArticle

67 Citations (Scopus)

Outcomes of the miltuximab first in human trial and proposed study design for a phase 1 trial 89zr/177lu theranostic trial

Campbell, D., Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Poursoultan, P., Ho Shon, K., Mackay, T., Roach, P., Bailey, D. & Walsh, B., 2019, In : European Urology, Supplements. 18, 1, p. e873 1 p., 655.

Research output: Contribution to journalMeeting abstract

Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial.

Campbell, D., Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Poursoultan, P., Ho Shon, K., Mackay, T., Bailey, D. L., Roach, P. & Walsh, B., 2019, In : Journal of Clinical Oncology. 37, 7 Supplement, p. 261 1 p.

Research output: Contribution to journalMeeting abstract

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Nam, K., Frenkl, T. L., Perini, R. F., De Wit, R. & Bajorin, D. F., 1 Jun 2019, In : Annals of Oncology. 30, 6, p. 970-976 7 p., mdz127.

Research output: Contribution to journalArticle

Open Access
File
21 Citations (Scopus)
13 Downloads (Pure)

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

Lee, C. I., Fox, P., Balakrishnar, B., Balleine, R. L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H. & Wilcken, N., 1 Aug 2019, In : Breast. 46, p. 52-57 6 p.

Research output: Contribution to journalArticle

2018

Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment

Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.

Research output: Contribution to journalArticle

Open Access
File
30 Citations (Scopus)
12 Downloads (Pure)

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.

Research output: Contribution to journalArticle

Open Access
File
5 Downloads (Pure)

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Rini, B. I., Tannir, N. M., Escudier, B., McDermott, D. F., Grimm, M. O., Porta, C., Powles, T., Kollmannsberger, C. K., Gurney, H. P., Tykodi, S. S., Harrison, M., Heng, D. Y. C., Grünwald, V., Choueiri, T. K., Mekan, S., McHenry, M. B., Hammers, H. J., Motzer, R. J. & George, S., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii309-viii310 2 p.

Research output: Contribution to journalMeeting abstract

Open Access
File
1 Downloads (Pure)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Gao, B., Lu, Y., Nieuweboer, A. J. M., Xu, H., Beesley, J., Boere, I., De Graan, A. J. M., De Bruijn, P., Gurney, H., Kennedy, C. J., Chiew, Y. E., Johnatty, S. E., Beale, P., Harrison, M., Luccarini, C., Conroy, D., Mathijssen, R. H. J., Harnett, P. R., Balleine, R. L., Chenevix-Trench, G. & 2 others, MacGregor, S. & De Fazio, A., 1 Dec 2018, In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508.

Research output: Contribution to journalArticle

Open Access
File
1 Citation (Scopus)
14 Downloads (Pure)

Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer

Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Li, H., Perini, R. F., Bajorin, D. F. & de Wit, R., 1 Jun 2018, In : Journal of Clinical Oncology. 36, 16, p. 1579-1587 12 p.

Research output: Contribution to journalArticle

28 Citations (Scopus)

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D., Choueiri, T. K., Necchi, A., Gerritsen, W. R., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Jensen, E., Frenkl, T., Perini, R. F. & Bajorin, D., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii320-viii321 2 p.

Research output: Contribution to journalMeeting abstract

Open Access
File

JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Motzer, R. J., Penkov, K., Haanen, J. B. A. G., Rini, B. I., Albiges, L., Campbell, M. T., Kollmannsberger, C. K., Negrier, S., Uemura, M., Lee, J. L., Gurney, H., Berger, R., Schmidinger, M., Larkin, J., Atkins, M. B., Wang, J., Robbins, P. B., Chudnovsky, A., Di Pietro, A. & Choueiri, T. K., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii724 1 p.

Research output: Contribution to journalMeeting abstract

Open Access
File

Nivolumab in the treatment of advanced renal cell carcinoma

Arasaratnam, M. & Gurney, H., Jul 2018, In : Future Oncology. 14, 17, p. 1679-1689 11 p., 29460635.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M. O., Bracarda, S. & 13 others, Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., Escudier, B. & CheckMate 214 Investigators, 5 Apr 2018, In : New England Journal of Medicine. 378, 14, p. 1277-1290 14 p.

Research output: Contribution to journalArticle

925 Citations (Scopus)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Powles, T., Motzer, R. J., Escudier, B., Pal, S., Kollmannsberger, C., Pikiel, J., Gurney, H., Rha, S. Y., Park, S. H., Geertsen, P. F., Gross-Goupil, M., Grande, E., Suarez, C., Markby, D. W., Arroyo, A., Dean, M., Choueiri, T. K. & George, D., 11 Sep 2018, In : British Journal of Cancer. 119, 6, p. 663-669 7 p.

Research output: Contribution to journalArticle

Open Access
File
18 Citations (Scopus)
95 Downloads (Pure)
6 Citations (Scopus)

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Guminski, A., Gurney, H., Sabanathan, D., Wong, S. & Pavlakis, N., Apr 2018, In : Asia-Pacific Journal of Clinical Oncology. 14, 2, p. e45-e49 5 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

The biodistribution of Miltuximab® using Gallium-67 nuclear imaging: the MILGa-01 first in human trial

Sabanathan, D., Gurney, H., Trifunovic, M., Poursoultan, P., Shon, K. H., Sia, T. R., Wissmueller, S., Roach, P., Bailey, D. L., Campbell, D. & Walsh, B. J., 2018, In : BJU International. 122, S2, p. 32-33 2 p., 074.

Research output: Contribution to journalMeeting abstract

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

McDermott, D. F., Rini, B. I., Motzer, R. J., Tannir, N. M., Escudier, B., Kollmannsberger, C. K., Hammers, H. J., Porta, C., George, S., Donskov, F., Gurney, H. P., Grimm, M-O., Harrison, M., Hutson, T. E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A. & Powles, T., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii309 1 p.

Research output: Contribution to journalMeeting abstract

Open Access
File
2017

A Distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer

PRIMe Consortium, 15 Nov 2017, In : International Journal of Cancer. 141, 10, p. 2112-2120 9 p.

Research output: Contribution to journalArticle

13 Citations (Scopus)

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program

Parente, P., Ng, S., Parnis, F., Guminski, A. & Gurney, H., Dec 2017, In : Asia-Pacific Journal of Clinical Oncology. 13, 6, p. 391-399 9 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

CheckMate 025 randomized Phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma

Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Peltola, K., Wagstaff, J., Gauler, T. C., Ueda, T., Zhao, H., Waxman, I. M., Motzer, R. J. & 1 others, CheckMate 025 Investigators, 2017, In : European Urology. 72, 6, p. 962-971 10 p.

Research output: Contribution to journalArticle

105 Citations (Scopus)

Communicating risk in active surveillance of localised prostate cancer: A protocol for a qualitative study

Rapport, F., Hogden, A., Gurney, H., Gillatt, D., Bierbaum, M., Shih, P. & Churruca, K., 1 Oct 2017, In : BMJ Open. 7, 10, p. 1-7 7 p., e017372.

Research output: Contribution to journalArticle

Open Access
File
6 Downloads (Pure)

Cure in advanced renal cell cancer: Is it an achievable goal?

Sabanathan, D., Park, J. J., Marquez, M., Francisco, L., Byrne, N. & Gurney, H., 1 Dec 2017, In : Oncologist. 22, 12, p. 1470-1477 8 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival

Patel, M. I., Beattie, K., Bang, A., Gurney, H. & Smith, D. P., Oct 2017, In : Cancer Medicine. 6, 10, p. 2188–2193 6 p.

Research output: Contribution to journalArticle

Open Access
File
14 Citations (Scopus)
2 Downloads (Pure)

Dose considerations for anti-cancer drugs in metastatic prostate cancer

Crumbaker, M. & Gurney, H., 1 Aug 2017, In : Prostate. 77, 11, p. 1199-1204 6 p.

Research output: Contribution to journalReview article

3 Citations (Scopus)

Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

Sabanathan, D., Zhang, A., Fox, P., Coulter, S., Gebski, V., Balakrishnar, B., Chan, M., Liddle, C. & Gurney, H., Aug 2017, In : Cancer Chemotherapy and Pharmacology. 80, 2, p. 385–393 9 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

e-TC: development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer

Heiniger, L. E., Smith, A. B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J-A. M., Price, M. A., McJannett, M., Tran, B., Stockler, M. R., Gurney, H. & Butow, P. N., Nov 2017, In : European Journal of Cancer Care. 26, 6, p. 1-10 10 p., e12698.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

Rowland, A., van Dyk, M., Mangoni, A. A., Miners, J. O., McKinnon, R. A., Wiese, M. D., Rowland, A., Kichenadasse, G., Gurney, H. & Sorich, M. J., 2017, In : Expert Opinion on Drug Metabolism and Toxicology. 13, 1, p. 31-49 19 p.

Research output: Contribution to journalReview article

30 Citations (Scopus)

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study

Colomba, E., Le Teuff, G., Eisen, T., Stewart, G. D., Fife, K., Larkin, J., Biondo, A., Pickering, L., Srinivasan, A., Boyle, H., Derosa, L., Sternberg, C. N., Recine, F., Ralph, C., Saldana, C., Barthélémy, P., Bernhard, J. C., Gurney, H., Verhoest, G., Vauleon, E. & 11 others, Bigot, P., Berger, J., Pfister, C., Gravis, G., Rodier, J-M., Culine, S., Caty, A., Rolland, F., Priou, F., Escudier, B. & Albiges, L., 1 Jul 2017, In : European Journal of Cancer. 80, p. 55-62 8 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

MILGa-01: a first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers

Gurney, H., Sabanathan, D., Gillatt, D., Poursoultan, P., Ho Shon, K., Walsh, B., Velonas, V., Thurecht, K. & Campbell, D., 2017, In : Journal of Clinical Oncology. 35, 6, 1 p., e565.

Research output: Contribution to journalMeeting abstract

Patient reported outcomes during long term treatment with PD-1 inhibitors focusing on chronic toxicity and quality of life

Man, J., Mercieca-Bebber, R., Habib, R., Carlino, M., Nagrial, A., Gao, B., Gurney, H., Wong, M. & Hui, R., 1 Nov 2017, In : Annals of Oncology. 28, Supplement 10, p. x192 1 p.

Research output: Contribution to journalMeeting abstract

Open Access